Condition 1: Overweight. Condition 2: Dyslipidemia. Condition 3: Low-grade systemic inflammation. Overweight Hyperlipidemia, unspecified
Conditions
Interventions
Intervention 1: Intervention group 1 (High-Intensity Functional Training):Three sessions per week for 8 weeks. Each session included 4 bouts of functional exercises (squat, deadlift, shoulder press, b
only participated in pre- and post-tests.
Sponsors
Faculty of Physical Education and Sport Sciences, University of Tehran
Eligibility
Sex/Gender
Male
Age
25 Years to 35 Years
Inclusion criteria
Inclusion criteria: Age between 25 and 35 years. Healthy overweight men (BMI between 25 and 29.9 kg/m²). No participation in regular and organized exercise programs in the last six months. Completion of informed consent form and medical health questionnaire.
Exclusion criteria
Exclusion criteria: Smoking during the past 6 months. Weight gain of more than 2 kg in the last 6 months. Participation in a weight loss program during the past 6 months. Engagement in heavy resistance training aimed at increasing muscle mass and strength during the past 6 months. Presence of chronic metabolic or endocrine diseases. Family history of early cardiac mortality. Inability to complete the exercise protocol (identified during the pilot phase). Use of any specific medication or supplement in the past six months History of cardiovascular diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood level of toll-like receptor 4 (TLR4). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzyme-linked immunosorbent assay using a human-specific commercial kit.;Blood level of matrix metalloproteinase 9 (MMP-9). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzyme-linked immunosorbent assay using a human-specific commercial kit.;Blood level of interferon-gamma (IFN-?). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzyme-linked immunosorbent assay using a human-specific commercial kit.;Blood level of interleukin-4 (IL-4). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzyme-linked immunosorbent assay using a human-specific commercial kit.;Fasting blood sugar (FBS). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzymatic method using an automatic biochemistry analyzer.;Total cholesterol (CHOL). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzymatic method using an automatic biochemistry analyzer.;High-density lipoprotein cholesterol (HDL). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzymatic method using an automatic biochemistry analyzer.;Low-density lipoprotein cholesterol (LDL). Timepoint: At baseline (before the start of the intervention) and After completing the 8-week intervention period. Method of measurement: Measured by enzymatic method u | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Shabkhiz
Faculty of Physical Education and Sport Sciences, University of Tehran
Outcome results
None listed